Dermatology

CVS Launches New Biosimilars Brand

September 6th 2023

By Skylar Jeremias

Article

CVS Health Corporation launched Cordavis, a new subsidiary that will work with manufacturers to commercialize and coproduce biosimilars, beginning with an adalimumab product.

Stelara and Enbrel Chosen for IRA Price Negotiation

August 29th 2023

By Skylar Jeremias

Article

Stelara (ustekinumab) and Enbrel (etanercept), 2 originator medications that will face biosimilar competition within the next decade, were among the 10 preliminary drugs chosen for Medicare price negotiation under the Inflation Reduction Act (IRA).

Meta-Analysis Confirms Clinical Equivalence Between RA Biosimilars, Originators

August 26th 2023

By Skylar Jeremias

Article

A meta-analysis and systematic review of data on over 10,000 patients with rheumatoid arthritis (RA) found that etanercept, adalimumab, and infliximab biosimilars were clinically equivalent to their reference products.

Cardinal Health Exec: How Adalimumab Biosimilars Can Reshape the US Health Care Industry

August 23rd 2023

By Skylar Jeremias

Article

Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, published her opinions on the future of biosimilars in the United States, foreshadowing immense growth and a transformation of the US health care industry thanks to biosimilars.

Contributor: The Promise of RA Biosimilars Could Be Realized, but Greater Adoption Rates Are Needed

August 14th 2023

By Robert Zutaut, RPh

Article

Robert Zutaut, RPh, a clinical specialist from McKesson Provider Solutions, quantifies the major barriers to adoption for biosimilars used to treat rheumatoid arthritis (RA) and some major considerations for health systems looking to address them.

Research Confirms Long-Term Stability of Adalimumab Biosimilar Candidate TUR01

August 12th 2023

By Deana Ferreri, PhD

Article

A study on the stability of the adalimumab biosimilar candidate TUR01, a tumor necrosis factor-α inhibitor, found long-term stability of the drug substance and drug product were maintained under different temperatures.

Spanish Psoriasis Working Group Revises Guidelines for Biosimilars in Psoriasis

August 10th 2023

By Skylar Jeremias

Article

The Spanish Psoriasis Working Group updated its position on the use of biosimilar medicines in patients with moderate to severe psoriasis, including its views on biosimilars as first-line treatment and nonmedical switching.

Despite Global Increase in Amjevita Sales, US Sales Dropped 63%

August 5th 2023

By Skylar Jeremias

Article

Despite global sales for Amjevita (adalimumab-atto) growing by 29% year-over-year and the agent being the first adalimumab biosimilar on the US market, sales in the United States dropped 63% from the first quarter to the second quarter of 2023.

Eye on Pharma: Interchangeability Study Results; Express Scripts to Cover Cyltezo; TDM for Idacio

August 3rd 2023

By Skylar Jeremias

Article

Samsung Bioepis and Organon released results from an interchangeability study of its adalimumab biosimilar; Express Scripts announced that it will add Cyltezo as well as 2 other adalimumab biosimilars to its formulary list; Anser Therapeutics will offer therapeutic drug monitoring (TDM) for Idacio.

Why Are Companies Launching Biosimilars With 2 Prices? Julie Reed Explains

July 30th 2023

By Skylar Jeremias

Video

Why are companies pricing their adalimumab biosimilars with 2 prices? Can the United States expect more of this pricing strategy for future biosimilar launches? Julie Reed, executive director of the Biosimilars Forum, has the answers.